Psyence Biomedical Ltd. (NASDAQ:PBM), a company listed on the Nasdaq Capital Market, is known for its work in the biomedical field. The company is currently in the spotlight due to its planned reverse stock split. A reverse stock split is a corporate action where a company reduces the number of its outstanding shares, which can help increase the stock price and make it more attractive to investors.
Initially, PBM announced a reverse stock split at a ratio of 1-for-6.25, set to take effect on January 20, 2026. However, the company has postponed this action, as highlighted by MarketBeat.com. The decision to delay the split came after internal discussions, and PBM plans to announce a new date in the future. Until then, the stock will continue trading under the symbol "PBM" without any adjustments.
Currently, PBM's stock is priced at $0.67, with a market capitalization of approximately $478,000. The stock has experienced significant volatility, with a 52-week high of $108.59 and a low of $0.615. The company's price-to-earnings (P/E) ratio is 0.17, indicating that the stock is trading at a low price relative to its earnings.
Despite the planned reverse stock split, analysts have a cautious outlook on PBM. Weiss Ratings has reaffirmed a "sell (e+)" rating, and the consensus rating from analysts is also "Sell." This suggests that investors should be cautious about the stock's future performance.
PBM's trading volume on the Nasdaq exchange is 506,821 shares, indicating active trading. The stock's 50-day moving average is $1.48, while the 200-day moving average is $3.18, reflecting a downward trend over the past year. The company's beta of 0.32 suggests that the stock is less volatile compared to the overall market.
